Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

Tuesday, 02 April, 2024 | Supplied by: Bio-Rad Laboratories Pty Ltd

Bio-Rad Laboratories has launched a range of validated antibodies for rare cell and circulating tumour cell (CTC) enumeration. Validated for use with the company’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumour heterogeneity and disease progression at various stages.

Bio-Rad’s Genesis Cell Isolation System is a customisable benchtop solution that uses unbiased size-based cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples. After capture, the enriched cells can be recovered for downstream analysis or immuno-stained on-slide for immunofluorescence applications such as enumeration and identification of various CTC types.

The enumeration of captured CTCs provides valuable insights into the surface markers that indicate cancer type and progression, and is critical to understanding the mechanisms of cancer metastasis. For successful enumeration, the antibody reagents require careful selection to ensure not only sensitivity and specificity to the target cell surface marker, but also compatibility with the staining method. Bio-Rad’s range of validated primary and secondary antibodies enables immunostaining of captured CTCs, supporting cancer researchers working in this field.

Phone: 02 9914 2800
Related Products

AlphaThera oYo-Link Antibody Labeling Reagents

AlphaThera's oYo-Link Antibody Labeling Reagents enable site-specific antibody labelling....

Bio-Rad Laboratories StarBright Red 715, 775 and 815 Dyes and expanded antibody markers

The StarBright Dyes — proprietary fluorescent nanoparticles conjugated to flow-validated...

RevMAb Biosciences histone family protein monoclonal antibodies

RevMAb Biosciences offers a wide range of recombinant monoclonal antibodies against histone...

  • All content Copyright © 2024 Westwick-Farrow Pty Ltd